The purpose of this study is to evaluate the safety and effectiveness of the Elevate System for patients needing non-emergent percutaneous coronary intervention (PCI).

The Elevate System is an investigational heart pump device, which means it has not been approved by the U.S. Food and Drug Administration (FDA). It is being compared with an already approved heart pump device called the Impella System. The Impella System is approved for patients having HR-PCI.

Participants will be randomized into one of two study groups. Randomization is like flipping a coin and there is an equal chance of being assigned to either group. Participants will not know what group they are assigned to.

Total participation in the study will last 90 days after the procedure. Participants will have two (2) follow-up telephone calls from the study staff to see how they are feeling.